Brief: Vivesto: Positive Results From Exploratory Study With Cantrixil
16/06/2026 07:05
BRIEF-Vivesto: Positive Results From Exploratory Study With Cantrixil June 16 (Reuters) - Vivesto AB VIVE.ST:
REPORTS POSITIVE RESULTS FROM EXPLORATORY PK AND TOXICOLOGY STUDY WITH CANTRIXIL
FIRST INTRAVENOUS CANTRIXIL STUDY IN LARGE ANIMAL (DOG) COMPLETED
STUDY SUPPORTS ONCE WEEKLY DOSING OF CANTRIXIL IN HUMANS AND DOGS
INTRAVENOUS CANTRIXIL WELL TOLERATED AT ALL DOSE LEVELS WITH NO NEGATIVE FINDINGS
PHARMACOKINETIC PARAMETERS OF CANTRIXIL IN LINE WITH EXPECTATIONS
DATA SUPPORTS FURTHER DEVELOPMENT OF CANTRIXIL TOWARDS PHASE I AML STUDY IN HUMANS
Source text: ID:nMFN8YT6M6
Further company coverage: VIVE.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Vivesto AB
See all newsBrief: Vivesto Reports Positive Topline Results From Paccal Vet Study In Cats
Brief: Vivesto Says Topline Results For Paccal Vet 'Positive'
Brief: Vivesto Q2 Operating Loss At SEK 8.6 Mln
Brief: Vivesto: Positive Results From Exploratory Study With Cantrixil
Brief: Vivesto Appoints Björn Svanström As CFO